GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Health and Human Services Secretary Robert F. Kennedy told people gathered at a funeral for a second child in Texas who died ...

The delay follows leadership changes within the FDA. Dr. Scott Steele has been appointed acting director of the agency’s ...

(Reuters) -Peter Marks, the FDA's top vaccine official ousted by Robert F. Kennedy Jr. said the U.S. health secretary's team ...

More top vaccine regulators at the FDA have either left or been forced out, which could hobble the agency's ability to ...

Kennedy Jr., and that the deputy commissioner at the FDA intervened in the ... which is contingent on the approval. But Sanofi can still go ahead with the vaccine rollout on the basis of the ...

But with FDA action, it would be the third vaccine against COVID-19 to receive full FDA approval. Full approval would make the vaccine available beyond an emergency declaration and could provide ...

VACCINE APPROVAL PAUSED — A top FDA official has pressed pause on the approval process for Novavax’s Covid-19 vaccine, according to four people familiar with the decision who were granted ...